CMS Reviewing Medtronic Activa Reimbursement For Bilateral Indication
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Medicare & Medicaid Services has initiated a national coverage review of Medtronic's Activa for bilateral brain stimulation in Parkinson's disease patients, but the agency will not reimburse the indication until it is approved by FDA.
You may also be interested in...
MCAC Panel Recommends Coverage Decision Of Bilateral DBS For Parkinson’s
Medicare coverage conditions for bilateral deep-brain stimulation to treat Parkinson's disease should stipulate that procedures be performed by a "specialized team" of movement-disorder neurologists and neurosurgeons, Medicare Coverage Advisory Committee panel members concluded June 12
MCAC Panel Recommends Coverage Decision Of Bilateral DBS For Parkinson’s
Medicare coverage conditions for bilateral deep-brain stimulation to treat Parkinson's disease should stipulate that procedures be performed by a "specialized team" of movement-disorder neurologists and neurosurgeons, Medicare Coverage Advisory Committee panel members concluded June 12
Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer
Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: